The synthesis of novel well-defined alkyne side chain functional polymers featuring narrow
molecular weight distributions (PDI = 1.09−1.17) by living radical polymerization is described. …

… This result is consistent with the replication mapping experiments (Figure 4), which show
that G residues are the preferential binding sites on polymeric DNA modified with complexes 4−…

Hypoxic tumours are a major problem for cancer photodynamic therapy. Here, we show that
photoredox catalysis can provide an oxygen-independent mechanism of action to combat …

Platinum complexes are the most widely used anticancer drugs; however, new generations
of agents are needed. The organoiridium(III) complex [(η 5 ‐Cp xbiph )Ir(phpy)(Cl)] (1‐Cl), …

Ruthenium dimer 6 (readily available in two steps from TsDPEN) is converted directly to
monomeric asymmetric transfer hydrogenation catalyst 3 in situ under the conditions employed …

Ruthenium dimer 4 is converted directly to monomeric asymmetric transfer hydrogenation
catalyst 2 under the conditions employed for ketone reduction. Using 0.25 mol % of either 4 or …

Platin mit Licht aktiviert: Der inerte Pt IV‐Diazidokomplex trans, trans, trans‐[Pt (N 3) 2 (OH)
2 (py) 2] verwandelt sich bei der Bestrahlung mit geringen Dosen sichtbaren Lichts in einen …

This study aims to test the divergent predictions of the chunking theory (Chase & Simon, 1973)
and template theory (Gobet & Simon, 1996a, 2000) with respect to the number of chunks …

The helicates—chiral assemblies of two or more metal atoms linked by short or relatively
rigid multidentate organic ligands—may be regarded as non-peptide mimetics of α-helices …

Catalytic anticancer metallodrugs active at low doses could minimize side-effects, introduce
novel mechanisms of action that combat resistance and widen the spectrum of anticancer-…